David Moskowitz

Eight Enterprises LLC (8VC) is a private equity/venture capital firm founded in 2015 by Joseph T. Lonsdale. The firm is headquartered in San Francisco, California.

Appia Bio, Inc. is an early stage biotechnology company based in an undisclosed location. Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. The American company utilizes the biology of lymphocyte development with chimeric antigen receptor (CAR) and T cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-NKT) or gamma delta T cells from hematopoietic stem cells (HSCs) with its ACUA (Appia Cells Utilized for Allogeneic) technology platform. The ACUA platform was developed from groundbreaking research in the laboratory of Lili Yang, Ph.D., at the University of California, and collaboration with Appia Bio's other scientific founders, David Baltimore, Ph.D. at Caltech and Pin Wang, Ph.D. at the University of Southern California. The company was founded in 2020 by Jeffrey S. Wiezorek, David Baltimore, Jeenjoo Kang, Lili Yang, Edmund Kim, and Pin Wang. Jeenjoo Kang has been the CEO since 2020.

Cartography Biosciences, Inc. is a biotech company that specializes in developing tumor-selective therapeutics using a unique genomics and computational platform. The company is based in Foster City, CA. The company integrates data from proprietary sample sourcing relationships, a comprehensive reference atlas, and target identification algorithms to identify the cells of interest and the single or pairs of targets that are most specific to the intended target cells. Cartography Biosciences is unlocking the full potential of immunotherapy by discovering and developing therapeutics as precise as their targets. The company was founded by Ansuman Satpathy, Howard Y. Chang, Kevin Parker. Kevin Parker has been the CEO since incorporation.